Table 1 Baseline characteristics of AF patients attending GUH, 2017 (N = 159)
Variable | All patients N = 159 | Undertreatment N = 103 | According to guideline treatment N = 56 | P-value |
|---|---|---|---|---|
Age in years | 0.09 | |||
 Mean ± SD | 58.50 ± 19.082 | 62.175 ± 16.215 | 51.732 ± 22.057 |  |
 Median (range) | 60 (18–90) | 65 (18–89) | 51 (18–90) | |
 IQR | 30 | 18.75 | 41.75 | |
Sex | 0.989 | |||
 Males | 51 (32.1%) | 33 (32.04%) | 18 (32.14%) |  |
Hemoglobin | ||||
 Mean ± SD | 13.328 ± 2.019 | 13.226 ± 2.246 | 13.518 ± 1.574 | 0.384 |
Serum creatinine | ||||
 Median (IQR) | 0.850 (0.32) | 0.890 (0.42) | 0.765 (0.34) | 0.026 |
SGOT | ||||
 Median (IQR) | 26.0 (26.95) | 27.100 (24.50) | 24.55 (38.75) | 0.668 |
SGPT | ||||
 Median (IQR) | 19.0 (24.3) | 18.00 (22.55) | 20.00 (33.53) | 0.214 |
AF clinical type | 0.003 | |||
 Valvular AF | 38 (23.9%) | 17 (16.5%) | 21 (37.5%) |  |
 NVAF | 121 (76.1%) | 86 (83.5%) | 35 (62.5%) | |
AF pattern | ||||
 Paroxysmal | 10 (6.3%) | 10 (9.7%) | 0 (0%) |  |
 Persistent | 98 (61.6%) | 71 (68.9%) | 27 (48.2%) | |
 Longstanding Persistent | 51 (32.1%) | 22 (21.4%) | 29 (51.8%) | |